Herpes simplex virus types 1 and 2 HSV1 and 2, namely varicella-zoster VZV and
cytomegalovirus CMV, are among the most common pathogens worldwide. They remain in …

Background The burden that cytomegalovirus (CMV) portends for haematopoietic and solid-
organ transplant recipients cannot be understated. Valganciclovir and ganciclovir have …

Background This drug resistance analysis of a randomized trial includes 234 patients
receiving maribavir and 116 receiving investigator-assigned standard therapy (IAT), where …

Background Neutropenia may limit the use of valganciclovir treatment for cytomegalovirus
(CMV) infection following hematopoietic cell transplant (HCT). A phase 2 study indicated …

Despite advances in monitoring and treatment, cytomegalovirus (CMV) infections remain
one of the most common complications after solid organ transplant (SOT). CMV infection …

Maribavir was approved by the US Food and Drug Administration in November 2021 for the
treatment of adult and pediatric patients with post-transplant cytomegalovirus (CMV) …

Cytomegalovirus (CMV), a member of the Herpesviridae family, is frequent among
hematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients in absence …

Preventing viral infections at an early stage is a key strategy for successfully improving
transplant outcomes. Preemptive therapy and prophylaxis with antiviral agents have been …

Cytomegalovirus (CMV) resistance testing by targeted next-generation sequencing (NGS)
allows for the simultaneous analysis of multiple genes. We developed and validated an …

Purpose of Review Cytomegalovirus (CMV) infections are a common complication in solid
organ (SOT) and hematopoietic stem cell transplant (HSCT) recipients, leading to increased …